Summary: Centessa Pharmaceuticals announced positive interim data from its ongoing phase 1 trial of ORX750, an orexin receptor 2 agonist, in acutely sleep-deprived healthy volunteers. The trial demonstrated that ORX750 significantly increased wakefulness, with the 2.5 mg dose … [Read more...]
FDA OKs Phase 1 Trial of Narcolepsy Drug Candidate ORX750
Summary: Centessa Prescription drugs has received Food and drug administration authorization to commence a section 1 demo of ORX750, an investigational oral therapy aimed at narcolepsy and other slumber-wake conditions. ORX750, a selective orexin receptor 2 agonist, addresses the … [Read more...]
Centessa on Track to Unveil ORX750 Data for Sleep Disorders
Essential Takeaways: Centessa Prescribed drugs claimed development in its orexin agonist software, spotlighting the possible of ORX750 to treat narcolepsy and other rest-wake diseases centered on promising preclinical details. ORX750 demonstrated usefulness in cutting down … [Read more...]